Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity

Discrepancies between HIV-1 RNA results assayed by different FDA-approved platforms have been reported. Plasma samples collected from 332 randomly selected clinical trial participants during the second year of antiretroviral treatment were assayed with three FDA-approved platforms: UltraSensitive Ro...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Microbiol
Главные авторы: Lalama, Christina M., Jennings, Cheryl, Johnson, Victoria A., Coombs, Robert W., McKinnon, John E., Bremer, James W., Cobb, Bryan R., Cloherty, Gavin A., Mellors, John W., Ribaudo, Heather J.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Microbiology 2015
Предметы:
Virology
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4508432/
https://ncbi.nlm.nih.gov/pubmed/26063861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JCM.00801-15
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы